AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02382406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (Phase I)
Description: MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Study NCT02382406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 (Phase II)
Description: MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Study NCT02350127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
Study NCT02350127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
Study NCT02350127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
Study NCT02350127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
Study NCT01972529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (lower baseline platelet count)
Description: 60 mg placebo (3 x 20 mg matching placebo tablets)
Study NCT01972529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag (higher baseline platelet count)
Description: 40 mg avatrombopag (2 x 20 mg tablets)
Study NCT01972529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (higher baseline platelet count)
Description: 40 mg placebo (2 x 20 mg matching placebo tablets)
Study NCT00783731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose midazolam
Study NCT01520818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
Study NCT01520818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
Study NCT01520818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administered subcutaneously (s.c., under the skin), twice a day
Study NCT00546780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tanespimycin
Description: Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
Study NCT00546780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
Study NCT01208948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,2 dithiolane 3 valeric acid
Description: 600 mg alpha lipoic acid per day
Study NCT01208948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1,2 dithiolane 3 valeric acid
Description: 600 mg alpha lipoic acid per day
Study NCT02316769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video laryngoscope
Description: Patient intubated with the King Vision Video Laryngoscope
Study NCT02316769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC video laryngoscope
Description: Intubation with the McGrath MAC video laryngoscope
Study NCT03581084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
Study NCT01797679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strength Training
Study NCT01797679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study NCT02174432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER
Description: nalbuphine HCl ER BID for up to 50 weeks
Study NCT03814798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus every 2 weeks pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
Study NCT03814798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus once a week pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
Study NCT03814798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% daily push versus 2 times per week pump
Description: IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
Study NCT03814798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% 150 mg/kg
Description: loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
Study NCT00441090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Study NCT00441090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag tablets
Description: Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Study NCT03630822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Advanced Directive
Description: The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
Study NCT03630822 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: standardized maintenance with the patient
Study NCT02017054 — intervention group
Intervention type: OTHER
Intervention: Cath
Description: No intervention - registry
Study NCT03324893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F-18]-FCH PET/MRI
Description: Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
Study NCT03058341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
Study NCT03058341 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
Study NCT01241149 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: anti-reflux surgery
Description: Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
Study NCT01241149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anti-reflux surgery
Description: Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
Study NCT03831243 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
Study NCT03831243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-conformal radiotherapy
Description: In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
Study NCT04040309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF injection
Description: Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
Study NCT04040309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: 1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
Study NCT01080222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg, twice daily
Study NCT01080222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 100-mg, twice daily
Study NCT01080222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
Study NCT01080222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa-2a
Description: subcutaneous injection, 180-mcg, once weekly
Study NCT01080222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: capsule, 400-mg, twice daily
Study NCT01445925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Description: Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
Study NCT01445925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation + linear lesions
Description: Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
Study NCT01445925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Substrate modification
Description: at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
Study NCT01445925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological Substrate modification
Description: at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
Study NCT04504331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral dose
Study NCT04504331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Oral Dose
Study NCT04504331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Description: IV contrast agent
Study NCT04504331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: IV contrast agent
Study NCT04504331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
Study NCT01980238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannula ileostomy
Study NCT01980238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: loop ileostomy
Study NCT01980238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAR
Study NCT01980238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LAR
Study NCT02608398 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
Study NCT04436666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motivational video production through virtual reality glasses
Description: Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
Study NCT04436666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Application
Description: Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
Study NCT01161979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules 100 mg
Study NCT01161979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonegran
Description: Zonegran Capsules 100 mg of EISAI INC
Study NCT02146313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC4064A
Description: Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
Study NCT03575572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
Study NCT02328209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
Study NCT03604653 — intervention group
Intervention type: DEVICE
Intervention: HIPEC
Description: Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
Study NCT03604653 — intervention group
Intervention type: DRUG
Intervention: Mitomycin c
Description: MMC 30mg@ T0, 10mg@T45 min
Study NCT03604653 — intervention group
Intervention type: DRUG
Intervention: CDDP 50
Description: 50mg/m2@T0
Study NCT04551885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study NCT03604653 — intervention group
Intervention type: DRUG
Intervention: CDDP 75
Description: 75mg/m2@T0
Study NCT03604653 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: 15mg/m2@T0
Study NCT04551885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study NCT01606566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex induced PCI of bleomycin
Description: Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
Study NCT02962011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knotless barbed suture
Description: uterine incision closure
Study NCT02962011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polyglactin 910
Description: uterine incision closure
Study NCT00901368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSTER
Description: CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
Study NCT00901368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
Study NCT05751629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab was administered.
Study NCT00657488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100mg/day or 400 mg/day at bed time during one year
Study NCT01448564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
Study NCT00657488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100mg/day or 400 mg/day at bed time during one year
Study NCT01448564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser therapy
Description: The application of laser therapy will be a low intensity laser.
Study NCT01116492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: One port placed through the umbilicus
Study NCT01116492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Standard 4 port laparoscopic cholecystectomy
Study NCT02192970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00897130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
Study NCT04012060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited access aortic valve replacement.
Description: Limited access aortic valve replacement through partial upper hemisternotomy
Study NCT04012060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aortic valve replacement
Description: Aortic valve replacement through full median sternotomy
Study NCT04012060 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional aortic valve replacement
Description: Aortic valve replacement through full median sternotomy